As previously reported, Needham analyst Serge Belanger downgraded Collegium Pharmaceutical to Hold from Buy. The company’s revenue missed the Street’s $146.9M forecast as weakness in both Xtampza and Nucynta offset Belbuca strength, the analyst tells investors in a research note. Collegium’s CEO departure will also lead to uncertainty regarding its growth plans and the search for a commercial asset, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical authorizes generic agreement with Hikma
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical announces redemption of convertible senior notes
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026